Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $478.75 Million |
|---|---|
| Enterprise Value | $438.93 Million |
| Earnings per Share | $-336 |
| Beta | 1.33 |
| Outstanding Shares | 12,004,791 |
| P/E Ratio | -1.88 |
|---|---|
| PEG | -1.76 |
| Price to Sales | - |
| Price to Book Ratio | 6.65 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.46 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Pha...